Mark Kendall has been central to the development of the Nanopatch, which potentially will revolutionise global vaccination. He conceived and patented the technology that distinguishes the Nanopatch from other intradermal delivery devices, led the research programme to take forward the device to proof-of-concept in the animal model, founded Vaxxas to take the Nanopatch into the clinic as a commercial product, led the R&D program and secured partnerships with Merck and the World Health Organisation for specific product development. I believe the Nanopatch has potential to be a significant game changer for vaccine delivery, vaccine innovation